AMAM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 kov. 2024 @ 23:00):

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform...

Stats
Šios dienos apimtis	1.42M
Vidutinė apimtis	1.94M
Rinkos kapitalizacija	1.77B
EPS	$0 ( 2024-04-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	66.67
ATR14	$0.381 (1.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	O'connor Daniel J.	Buy	750 000	Common Stock
2023-10-27	O'connor Daniel J.	Sell	50 012	Common Stock
2023-10-23	Cormorant Asset Management, Lp	Buy	1 307 311	Common Stock
2023-09-18	Cormorant Asset Management, Lp	Buy	751 233	Ordinary Shares
2023-09-15	Cormorant Asset Management, Lp	Buy	1 401 505	Ordinary Shares

INSIDER POWER
64.11
Last 64 transactions
Buy: 36 374 710 \| Sell: 11 079 608

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: -0.26 (neutral)

Signal:(82.204) Neutral

Ambrx Biopharma Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MSP	0.95
RXN	0.934
UVE	0.934
MOG-B	0.927
KDMN	0.925
DCT	0.922
WST	0.921
AIW	0.918
BGSX	0.915
FCN	0.914

10 Labiausiai neigiamai susiję koreliacijos
LUMN	-0.94
KT	-0.934
AFI	-0.926
QGEN	-0.924
GEO	-0.92
NSC	-0.917
EQC	-0.912
UBA	-0.907
ATTO	-0.907
PDS	-0.906

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ambrx Biopharma Inc. Koreliacija - Valiuta/Žaliavos

0.95
( very strong )

0.92
( very strong )

-0.77
( moderate negative )

0.83
( strong )

0.23
( neutral )

-0.60
( weak negative )

Ambrx Biopharma Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$7.40M
Bruto pelnas:	$7.40M (100.00 %)
EPS:	$-2.02

FY	2022
Pajamos:	$7.40M
Bruto pelnas:	$7.40M (100.00 %)
EPS:	$-2.02

FY	2021
Pajamos:	$7.46M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.36

FY	2020
Pajamos:	$13.67M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Ambrx Biopharma Inc.

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.